NCT03011372 2025-11-18A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)Incyte CorporationPhase 2 Completed47 enrolled 21 charts 1 FDA